Tagging a new therapy onto an existing and widely used therapy can be an efficient, expedient and profitable way to enter the marketplace. It also removes the possibility of the new tech being buried by BP to protect their existing market. I absolutely hope that 225 goes down this path, at least in the early stages for HIV. As for COVID, if the trials are successful then that would be a different story. I think that would be a go it alone scenario.
Tagging a new therapy onto an existing and widely used therapy...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.72M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.4¢ | 5.2¢ | $2.393K | 44.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19600 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 188178 | 2 |
View Market Depth
| Last trade - 15.15pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.4¢ |
Change
0.000 ( 3.85 %) |
||||
| Open | High | Low | Volume | ||
| 5.4¢ | 5.4¢ | 5.2¢ | 120722 | ||
| Last updated 15.15pm 03/05/2024 ? | |||||
| BIT (ASX) Chart |